Literature DB >> 15485606

Treatment of lipids and type 2 diabetes.

Kathie L Hermayer1.   

Abstract

The development of type 2 diabetes is increasing in epidemic proportions. There is a significant risk for cardiovascular disease, which is the most prevalent and detrimental complication for the diabetic population. Serum lipid abnormalities are common in patients with diabetes, and due to this increased vascular risk, it is recommended to aggressively treat the hyperlipidemia. Therefore, intensive lipid-lowering therapy should be used for primary and secondary prevention against macrovascular complications for patients with type 2 diabetes. In this article some of the key studies justifying the need for lipid reduction in patients with type 2 diabetes are reviewed and practical guidelines for management of the dyslipidemia are suggested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485606     DOI: 10.1007/s11886-004-0053-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  46 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Dyslipidemia management in adults with diabetes.

Authors:  Steven M Haffner
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

3.  Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus.

Authors:  M Chandalia; A Garg; D Lutjohann; K von Bergmann; S M Grundy; L J Brinkley
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

4.  Dietary supplementation with n-3 fatty acids may impair glucose homeostasis in patients with non-insulin-dependent diabetes mellitus.

Authors:  B Vessby; M Boberg
Journal:  J Intern Med       Date:  1990-08       Impact factor: 8.989

5.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Authors:  Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

6.  Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

Authors:  B J Hoogwerf; A Waness; M Cressman; J Canner; L Campeau; M Domanski; N Geller; A Herd; A Hickey; D B Hunninghake; G L Knatterud; C White
Journal:  Diabetes       Date:  1999-06       Impact factor: 9.461

7.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

10.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.